Navigation Links
Lux Biosciences' Investigational Therapy for Uveitis, LX211, is,Subject of Two Presentations at Key Ophthalmology Meeting, ARVO,2007

ilicone matrix ocular (episcleral) implant that steadily releases therapeutic doses of cyclosporine A locally to the eye. Both the LUMINATE pivotal clinical program for LX211 for the treatment of uveitis, as well as the LUCIDA pivotal clinical program with LX201 for the prevention of corneal transplant rejection were initiated in early 2007.

-- A proprietary product-enabling bio-erodible polymer technology that facilitates targeted and sustained delivery of molecules to the eye.

For more information on Lux Biosciences, please visit the company's website at www.luxbio.com.

Contact

Lux Biosciences, Inc.
Ulrich Grau, Ph.D., +1 201-946-0221
Ulrich.grau@luxbio.com
or
Kureczka/Martin Associates
Joan Kureczka, +1 415-821-2413 (Media)
Jkureczka@comcast.net


'"/>




Page: 1 2 3 4

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents

Post Your Comments:
(Date:11/6/2009)...PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: ...ping products for minimally disruptive surgical tr...tment of Michael J. Lambert as Executive Vice Pres...ber 9, 2009. The Company also announced several o...hael will be an excellent complement to the NuVasi...
(Date:11/6/2009)... Nov. 6 With his proposed health c...s sights on cutting name-brand prescription drug c...into the "Part D" coverage gap, universally known ... potential cost-cutting and feel it,s a promising ...powerful lobbyists want a revised program that com...
(Date:11/6/2009)...Newswire-FirstCall/ -- Cyberonics, Inc. (Nasdaq: ...t financial results for the second quarter ended O..., 2010 on Wednesday, November 18, 2009 at 5:00 PM ...o discuss those results on Thursday, November 19, ...nd Quarter Results Conference Call Instructions ...
Breaking Medicine Technology:NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 2NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 3NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 4NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 5Obama Healthcare Reforms Fall Short, but Betterthanmedicare.com Closes the 'Donut Hole' 2Obama Healthcare Reforms Fall Short, but Betterthanmedicare.com Closes the 'Donut Hole' 3Cyberonics Announces Conference Call to Discuss Fiscal Year 2010 Second Quarter Financial Results 2Motion analysis helps soccer players get their kicks 51204 1Motion analysis helps soccer players get their kicks 51204 2Motion analysis helps soccer players get their kicks 51204 3Landmark project to map genomics of complex ant systems 9188 1Landmark project to map genomics of complex ant systems 9188 2Spread your sperm the smart way 9186 1Spread your sperm the smart way 9186 2Spread your sperm the smart way 9186 3
...Albuferon(R) for hepatitis C and LymphoStat-B(R) f...ial launch in 2010 -,- ABthrax(TM) for inhalation ...- Pipeline strengthened with investments in oncolo...ets initiative - - GSK to advance darapladib ... May 28 Human Genome Sciences,Inc. (Nasdaq: HGSI...
...rst Phase III study performed solely in high risk ...ovement in Disease Free Survival (DFS), BRIDGEWAT... Espanol de Investigacion en Cancer de Mama) annou...tive early stage breast cancer,adjuvant treatment ...ion,Concentrate as part of the TAC regimen (Taxote...
Other Medicine Technology:Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 2Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 3Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 4Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 5Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 6Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 7Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 8Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 9Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 10Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 11Node-Negative Early Stage Breast Cancer Patients Benefit from Taxotere(R)-Based Chemotherapy 2Node-Negative Early Stage Breast Cancer Patients Benefit from Taxotere(R)-Based Chemotherapy 3Node-Negative Early Stage Breast Cancer Patients Benefit from Taxotere(R)-Based Chemotherapy 4Node-Negative Early Stage Breast Cancer Patients Benefit from Taxotere(R)-Based Chemotherapy 5
(Date:11/8/2009)... AARP Praises House Passage of Health Care Reform...n Medicare, improve coverage for all Americans ,...SUMMARY: Tonight the United States House of Repre...slation that would strengthen Medicare for seniors...t prices millions of Americans out of affordable h...
(Date:11/7/2009)... WASHINGTON , Nov. 7 ...ay in support of H.R. 3962, the Affordable Health ...legislation later tonight. Below are the Speaker,... know, is an historic moment for our nation and fo...s of every party and political philosophy -- as fa...
(Date:11/7/2009)... Jacquelyn T. Coleman (CT), David A. Cook (GA), L...L. Tarver (LA) Honored ,, CHICAGO, Nov. 7 /PRN...ation (AMA) today presented five medical society e...their contributions to the goals and ideals of the...the AMA,s semi-annual policy making meeting in Hou...
(Date:11/7/2009)... WASHINGTON, Nov. 7 Wit...g, antichoice extremists are holding the entire bi...hey are demanding that the bill go far beyond the ...incorporated into the original bill. In an outrag...arly Saturday afternoon, antichoice Democrats are ...
(Date:11/7/2009)... WASHINGTON, Nov. 7 Spe...ess availability this afternoon following a Democr...on Caucus Room. Below are the Speaker,s opening r...s, it was a great occasion for us to receive the P...will be making history with our vote and making pr...
Breaking Medicine News(10 mins):Health News:AARP Maryland Key Vote News Alert 2Health News:AARP Maryland Key Vote News Alert 3Health News:Pelosi: Health Legislation Founded on Key Principles for a Healthier America: Innovation, Competition and Prevention 2Health News:Pelosi: Health Legislation Founded on Key Principles for a Healthier America: Innovation, Competition and Prevention 3Health News:Pelosi: Health Legislation Founded on Key Principles for a Healthier America: Innovation, Competition and Prevention 4Health News:AMA Honors Medical Society Executives 2Health News:Pelosi Remarks Following House Democrats' Meeting with President Obama 2
...nd Earnings per Share for the Year, CHICAGO, Feb....software, connectivity and information solutions t...nounced results for the three,months and year ende... 2007 was $73.4,million, compared to $63.6 million...
... Eye Institute (NEI) and the Food and Drug Adminis...er new disease-relevant outcome measures appropria..., clinical drug trials for glaucoma therapies rely...alities and changes in the optic nerve structure a...
...rnor Edward G.,Rendell today received a blueprint ...nia billions of dollars as the commonwealth become...ays for treatment of chronic diseases,while signif... part of the,Governor,s Prescription for Pennsylva...
...nior Living Inc.,(NYSE: BKD ) announced today tha...year 2007 financial results after the market close...scheduled a conference call to discuss,the results...side of the U.S.) ten minutes prior to the schedul...
...Feb. 13 Quintiles,Transnational Corp. today annou... certified by the College of American Pathologists...ng clinical trials in the first,quarter of 2007. T... commitment to providing high-quality,central labo...
...February 13, 2008) -- Sanofi Pasteur, the vaccines...he first application in Europe to deliver a vaccin...system developed by BD (Becton, Dickinson and Comp...fi Pasteur conducted clinical trials on more than ...
Other Medicine News:Health News:Allscripts Reports Fourth Quarter 2007 Results 2Health News:Allscripts Reports Fourth Quarter 2007 Results 3Health News:Allscripts Reports Fourth Quarter 2007 Results 4Health News:Allscripts Reports Fourth Quarter 2007 Results 5Health News:Allscripts Reports Fourth Quarter 2007 Results 6Health News:Allscripts Reports Fourth Quarter 2007 Results 7Health News:Allscripts Reports Fourth Quarter 2007 Results 8Health News:Allscripts Reports Fourth Quarter 2007 Results 9Health News:Allscripts Reports Fourth Quarter 2007 Results 10Health News:Upcoming meeting will explore new technologies for glaucoma clinical drug trials 2Health News:PA Governor Rendell Says Pennsylvania Again Leads the Nation With Introduction of Chronic Care Management Plan 2Health News:PA Governor Rendell Says Pennsylvania Again Leads the Nation With Introduction of Chronic Care Management Plan 3Health News:PA Governor Rendell Says Pennsylvania Again Leads the Nation With Introduction of Chronic Care Management Plan 4Health News:Brookdale Announces Fourth Quarter and Full Year 2007 Release and Earnings Call 2Health News:Quintiles Central Laboratory in India Receives CAP Certification 2Health News:1st EMEA application filed for product using innovative intradermal microinjection system BD Soluvia 2
Alger Brush Mk II
Diamond Burr 5.0mm (5086)
Ophthalmic Burr
Khosla Non-Illuminated Trial Lens Set, With Lenses Mounted
Medicine Products: